Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01698060 · ClinicalTrials.gov registry record · Phase 1
Immunogenicity of ND1.1 by Delivery Directly to the Ileum
A Phase 1 study, sponsored by Vaxart.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT01698060 is a Phase 1 study that has completed, run by Vaxart. The registered enrollment target is 12 participants.
The verdict
NCT01698060, a Phase 1 study, has completed, sponsored by Vaxart.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of the study is to determine the safety and tolerability of ND1.1, an adjuvanted adenoviral-based avian influenza vaccine, when delivery is targeted to the ileum, using a radio controlled capsule. The secondary objective is to evaluate the immune response (cellular and humoral) of two doses of ND1.1 oral vaccine.
Interventions
- BIOLOGICAL ND1.1
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2012-09 |
| Est. Completion | 2013-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01698060
The ClinicalTrials.gov registry entry for NCT01698060 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vaxart, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ND1.1 is the first listed.
NCT01698060 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01698060 about?
NCT01698060 is a clinical study titled "Immunogenicity of ND1.1 by Delivery Directly to the Ileum". The purpose of the study is to determine the safety and tolerability of ND1.1, an adjuvanted adenoviral-based avian influenza vaccine, when delivery is targeted to the ileum, using a radio controlled capsule. The secondary objective is to evaluate the immune response (cellular and humoral) of two do...
What is the current status of trial NCT01698060?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2012-09. Estimated completion is 2013-11.
What interventions are being tested in trial NCT01698060?
The interventions under investigation include: ND1.1 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01698060?
This trial is sponsored by Vaxart, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.